Skip to main content
SpringerLink
Log in
Book cover

The New Political Economy of Pharmaceuticals pp 1–28Cite as

Palgrave Macmillan

The New Political Economy of Pharmaceuticals: Conformity and Resistance in the Global South

  • Chapter

Part of the book series: International Political Economy Series ((IPES))

Abstract

Some two decades will shortly have passed since the World Trade Organization’s Agreement on Trade Related Aspects of Intellectual Property Rights (henceforth WTO and TRIPS) came into force in 1995 (World Trade Organization, 1994). TRIPS has proven to be one of the most politically charged and divisive multilateral agreements yet negotiated. The agreement has polarized opinion with regard to its effects on knowledge production and consumption in areas as diverse as agriculture and food security, literacy and education, software and the internet economy, and its general implications for capitalist accumulation.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   54.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Abbott, F. M. and J. H. Reichman (2007) ‘The Doha Round’s Public Health Legacy: Strategies for the Production and Diffusion of Patented Medicines under the Amended TRIPS Provisions’, Journal of International Economic Law 10, 921–87.

    Article  Google Scholar 

  • AstraZeneca (2011) ‘Annual Report and Form 20-F Information’, Retrieved from http://www.astrazeneca-annualreports.com/2011/documents/pdfs/annual_report_pdf_entire.pdf, date accessed 20 October 2012.

  • Baker, B. K. (2004) Processes and Issues for Improving Access to Medicines Willingness and Ability to Utilise TRIPS Flexibilities in Non-Producing Countries, Issues paper Access to medicines (London: DFID Health Systems Resource Centre).

    Google Scholar 

  • Baker, B. K. and T. Avafia (2011) ‘The Evolution of IPRs from Humble Beginnings to the Modern Day TRIPS-Plus Era: Implications for Treatment Access’, Working Paper prepared for the Third Meeting of the Technical Advisory Group of the Global Commission on HIV and the Law, 7–9 July 2011, Global Commission on HIV and the Law.

    Google Scholar 

  • Ballance, R. H., J. Pogány, and H. Forstner (1992) TheWorld’s Pharmaceutical Industries: An International Perspective on Innovation, Competition and Policy (Aldershot: Edward Elgar). Beall, R. and R. Kuhn (2012) ‘Trends in Compulsory Licensing of Pharmaceuticals since the Doha Declaration: A Database Analysis’, PLoS Med 9, e1001154.

    Article  Google Scholar 

  • Boldrin, M. and D. K. Levine (2008) ‘Against Intellectual Monopoly’, http://www.dklevine.com/general/intellectual/againstfinal.htm, date accessed 11 September 2012.

  • Bower, D. J. and J. C. Sulej (2007) ‘The Indian Challenge: The Evolution of a Successful New Global Strategy in the Pharmaceutical Industry’, Technology Analysis & Strategic Management 19, 611–24.

    Article  Google Scholar 

  • Chaudhuri, S. (2010) ‘R&D for Development of New Drugs for Neglected Diseases in India’, International Journal of Technology and Globalisation 5, 61–75.

    Article  Google Scholar 

  • Chien, C. (2003) ‘Cheap Drugs at What Price to Innovation: Does Compulsory Licensing of Pharmaceuticals Hurt Innovation?’, Berkeley Technology Law Journal 18, 853–907.

    Google Scholar 

  • Committee on Economic Social and Cultural Rights (2000) The Right to the Highest Attainable Standard of Health (Art. 12) (Geneva: United Nations High Commissioner for Human rights).

    Google Scholar 

  • Correa, C. (2002) Implications of the Doha Declaration on the TRIPS Agreement and Public Health (Geneva: World Health Organization).

    Google Scholar 

  • Correa, C. M. (2001) ‘The WTO Dispute Settlement Mechanism: TRIPS Rulings and the Developing Countries’, The Journal of World Intellectual Property 4, 251–5.

    Article  Google Scholar 

  • Correa, C. M. (2011) Pharmaceutical Innovation, Incremental Patenting and Compulsory Licensing, Research Paper 41 (Geneva: South Centre).

    Google Scholar 

  • Deere, C. (2009) The Implementation Game: The TRIPS Agreement and the Global Politics of Intellectual Property Reform in Developing Countries (Oxford: Oxford University Press).

    Google Scholar 

  • Drahos, P. and J. Braithwaite (2001) ‘Intellectual Property, Corporate Strategy, Globalisation: TRIPS in Context’, Wisconsin International Law Journal 19, 451–80.

    Google Scholar 

  • Drahos, P. and J. Braithwaite (2002) Information Feudalism: Who Owns the Knowledge Economy? (London: Earthscan).

    Google Scholar 

  • Drahos, P. and J. Braithwaite (2004) Who Owns the Knowledge Economy: Political Organising Behind TRIPS, Briefing Paper 32 (London: The Corner House). El Said, M. (2005) ‘The Road from TRIPS-Minus, to TRIPS, to TRIPS-Plus: Implications of IPRs for the Arab World’, The Journal of World Intellectual Property 8, 53–65.

    Google Scholar 

  • El Said, M. K. (2010) Public Health Related TRIPS-Plus Provisions in Bilateral Trade Agreements: A Policy Guide for Negotiators and Implementers in the Eastern Mediterranean Region (Cairo: World Health Organization).

    Google Scholar 

  • Flynn, S., A. Hollis, and M. Palmedo (2009) ‘An Economic Justification for Open Access to Essential Medicine Patents in Developing Countries’, The Journal of Law, Medicine & Ethics 37, 184–208.

    Article  Google Scholar 

  • Ganji, S. K. (2011) ‘TRIPS Implementation and Strategic Health Policy in India and Brazil’, Josef Korbel Journal of Advanced International Studies 3, 29–58.

    Google Scholar 

  • Global Commission on HIV and the Law (2012) Regional Issues Brief: Intellectual Property Rights and Access to Medicines. For the Africa Regional Dialogue of the Global Commission on HIV and the Law (New York: United Nations Development Programme).

    Google Scholar 

  • Godwin, J. (2011) Regional Issues Brief: Intellectual Property Rights and Access to Medicines (New York: Global Commission on HIV and the Law).

    Google Scholar 

  • Hanim, L. and H. Jhamtani (2006) ‘Indonesia: Manufacturing Generic Aids Medicines under the “Government Use” Approach’, Third World Resurgence 196. http://www.twnside.org.sg/title2/twr196.htm, date accessed 12 March 2012

  • Helfer, L. R. (2004) ‘Regime Shifting: The TRIPS Agreement and New Dynamics of International Intellectual Property Lawmaking’, Yale Journal of International Law 29, 1–84.

    Google Scholar 

  • Hermann, R. M. (2011) ‘Developing Countries Are Not Making the Most of TRIPS Flexibilities Because of Political Pressure’, British Medical Journal 343, d7706.

    Article  Google Scholar 

  • Ho, C. M. (2008) ‘On Breaking Patents: Separating Strands of Fact from Fiction under TRIPS’, http://works.bepress.com/cynthia_ho/2/, date accessed 1 August 2012.

  • Hogerzeil, H. V., M. Samson, J. V. Casanovas, and L. Rahmani-Ocora (2006) ‘Is Access to Essential Medicines as Part of the Fulfilment of the Right to Health Enforceable through the Courts?’ The Lancet 368, 305–11. Hollis, A. (2007) ‘Drugs for Neglected Diseases: New Incentives for Innovation’

    Google Scholar 

  • In F. A. Sloan and C.-R. Hsieh (eds), Pharmaceutical Innovation: Incentives, Competition, and Cost-Benefit Analysis in International Perspective (pp. 75–90, Cambridge: Cambridge University Press).

    Google Scholar 

  • Hunt, V., N. Manson, and P. Morgan (2011) ‘AWake-up Call for Big Pharma’. McKinsey Quarterly, December, https://www.mckinseyquarterly.com/A_wake-up_call_for_Big_Pharma_2897/A_wake-up_call_for_Big_Pharma_2897, date accessed 8 July 2012.

  • IMAP (2012) ‘Global Pharma & M&A Report 2012’. http://www.imap.com/imap/media/resources/Pharma_Report_2012_FINAL_2F6C8ADA76680.pdf, date accessed 8 August 2012.

  • Joint United Nations Programme on HIV/AIDS (2012) The Potential Impact of Free Trade Agreements on Public Health (Geneva: UNAIDS).

    Google Scholar 

  • Kaitin, K. I. and J. A. DiMasi (2011) ‘Pharmaceutical Innovation in the 21st Century:New Drug Approvals in the First Decade, 2000–2009’, Clinical Pharmacology and Therapeutics 89, 183–8.

    Article  Google Scholar 

  • Kanavos, P., L. Seeley, and S. Vandoros (2009) Tender Systems for Outpatient Pharmaceuticals in the European Union: Evidence from the Netherlands, Germany and Belgium (Brussels: European Commission).

    Google Scholar 

  • Kaplan, W. and R. Laing (2005) Local Production of Pharmaceuticals: Industrial Policy and Access to Medicines, Health, Nutrition and Population (HNP) Discussion Paper (Washington, DC: The International Bank for Reconstruction and Development/ The World Bank).

    Google Scholar 

  • Kohr, M. (2009) Patents, Compulsory Licences and Access to Medicines: Some Recent Experiences, Intellectual Property Rights Series 10 (Penang: Third World Network). http://www.twnside.org.sg/title2/IPR/pdf/ipr10.pdf, date accessed 13 August 2012.

  • Lee, S. H. and A. Y. Choi (2012). ‘Korean Patent Laws Amended in Order to Implement Korea-US FTA,’ Retrieved from http://www.kimchang.com/mailzine.asp?mailzine_no=1110, date accessed 12 September 2012.

  • Lindstrom, B. (2010) ‘Scaling Back TRIPS-Plus: An Analysis of Intellectual Property Provisions in Trade Agreements and Implications for Asia and the Pacific’, New York University Journal of International Law and Politics 42, 917–80.

    Google Scholar 

  • Lofgren, H. (2007) ‘The Global Biopharma Industry and the Rise of Indian Drug Multinationals: Implications for Australian Generics Policy’, Australia New Zealand Health Policy 4, 10.

    Article  Google Scholar 

  • Love, J. (2011) ‘What’s (Still) Wrong with ACTA, and Why Governments Should Reject the Illegitimate Agreement,’ http://keionline.org/node/1369/node/1369,date accessed 1 July 2012.

  • Love, J. and T. Hubbard (2007) ‘The Big Idea: Prizes to Stimulate R&D for New Medicines’, Chicago-Kent Law Review 82, 1519–53. Love, J. P. (2007) ‘Recent Examples of the Use of Compulsory Licences on Patents[1].

    Google Scholar 

  • KEI RN 2007:2’,http://keionline.org/content/view/41/1/content/view/41/1, 4 September 2012.Lyn,T. E.(2012) ‘China Changes Patent Law in Fight for Cheaper Drugs’,Reuters.http://www.reuters.com/article/2012/06/08/us-china-medicines-patentsidUSBRE8570TY20120608/article/2012/06/08/us-china-medicines-patentsidUSBRE8570TY20120608, date accessed 1 September 2012.

  • Matthews, D. and V. Munoz-Tellez (2006) ‘Bilateral Technical Assistance and TRIPS: The United States, Japan and the European Communities in Comparative Perspective’, Journal of World Intellectual Property 9, 629–53.

    Article  Google Scholar 

  • Médecins Sans Frontières (2012) ‘Trading Away Health: How the U.S. Intellectual Property Demands for the Trans-Pacific Partnership Agreement Threaten Access to Medicines’, http://aids2012.msf.org/wp-content/uploads/2012/07/TPPIssue-Brief-IAC-July2012.pdf/wp-content/uploads/2012/07/TPPIssue-Brief-IAC-July2012.pdf, date accessed 18 August 2012.

  • Mello e Souza, A. (2013) ‘The Politics of AIDS Treatment in Brazil: Patents and Access to Medicines’. In H. Löfgren (ed.), The Politics of Pharmaceuticals and Access to Medicines: World Pharmacy and India (pp. 272–99, New Delhi: Social Science Press).

    Google Scholar 

  • Micara, A. G. (2012) ‘TRIPS-Plus Border Measures and Access to Medicines’, Journal of World Intellectual Property 15, 73–101.

    Google Scholar 

  • Munos, B. (2009) ‘Lessons from 60 Years of Pharmaceutical Innovation’, [10.1038/nrd2961], Nature Reviews Drug Discovery 8, 959–68.

    Article  Google Scholar 

  • Musungu, S. and G. Dutfield (2003) Multilateral Agreements and a TRIPS-Plus World: The World Intellectual Property Organisation (Wipo), TRIPS Issues Papers 3 (Geneva: QUNO). Muzaka, V. (2011) The Politics of Intellectual Property Rights and Access to Medicines (Basingstoke: Palgrave Macmillan).

    Google Scholar 

  • Odell, J. S. and S. K. Sell (2003) ‘Reframing the Issue: The WTO Coalition on Intellectual Property and Public Health, 2001’, Paper presented at the conference on developing countries and the trade negotiation process, UNCTAD, 6–7 November 2003, Geneva.

    Google Scholar 

  • Pfizer (2012) ‘Annual Review 2011’, http://www.pfizer.com/investors/financial_reports/annual_reports/2011/biopharmaceutical.jsp,dateaccessed 30 August 2012.Pilla, V.(2012)‘Natco Targets Drugs Ripe for Compulsory Licensing’, http://www.livemint.com/Companies/ZR7YHsT0xTb6e9ppKDIAuN/Natco-targets-drugs-ripefor-compulsory licensing.html/Companies/ZR7YHsT0xTb6e9ppKDIAuN/Natco-targets-drugs-ripefor-compulsory%20licensing.html, date accessed 4 September 2012.

  • Reichman, J. H. (2009) ‘Comment: Compulsory Licensing of Patented Pharmaceutical Inventions: Evaluating the Options’, The Journal of Law, Medicine & Ethics 37, 247–63.

    Article  Google Scholar 

  • Report of the Commission on Intellectual Property Rights, Innovation and Public Health (2006) (Geneva: World Health Organization). http://www.who.int/intellectualproperty/report/en/index.html, date accessed 1 January 2012. Rezaie, R., A. McGahan, S. Frew, A. Daar, and P. Singer (2012) ‘Emergence of Biopharmaceutical Innovators in China, India, Brazil, and South Africa as Global Competitors and Collaborators’, Health Research Policy and Systems 10, 18.

    Article  Google Scholar 

  • Rushton, S. and O. D. Williams (eds) (2011). Partnerships and Foundations in Global Health Governance (Basingstoke: Palgrave Macmillan).

    Google Scholar 

  • Sell, S. K. (2002) ‘TRIPS and the Access to Medicines Campaign’,Wisconsin International Law Journal 20, 481–522.

    Google Scholar 

  • Sell, S. K. (2003) Private Power, Public Law: The Globalization of Intellectual Property Rights (Cambridge, UK: Cambridge University Press). Sell, S. K. (2006) ‘Books, Drugs and Seeds: The Politics of Access’, Paper presented at the Transatlantic Consumer Dialogue The Politics and Ideology of Intellectual Property, 20–21 March 2006, Brussels. Sell, S. K. (2010) ‘The Rise and Rule of a Trade-Based Strategy: Historical Institutionalism and the International Regulation of Intellectual Property’, Review of International Political Economy 17, 762–90.

    Google Scholar 

  • Sell, S. K. (2011) ‘TRIPS was Never Enough: Vertical Forum Shifting, FTAs, ACTA, and TPP’, Journal of Intellectual Property Law 18, 447–78.

    Google Scholar 

  • Smith, B. D. (2011) The Future of Pharma: Evolutionary Threats and Opportunities (Farnham: Ashgate).

    Google Scholar 

  • Srinivasan, S. (2012) ‘The Compulsory Licence for Nexavar: A Landmark Order’, Economic and Political Weekly 47, 10–13.

    Google Scholar 

  • Tempest, B. (2010) ‘A Structural Change in the Global Pharmaceutical Market’, Journal of Generic Medicines 7, 113–17.

    Article  Google Scholar 

  • ’t Hoen, E. F. M. (2009) The Global Politics of Pharmaceutical Monopoly Power: Drug Patents, Access, Innovation and the Application of the WTO Doha Declaration on Trips and Public Health (Diemen: AMB Publishers).

    Google Scholar 

  • Third International Consultation on HIV/AIDS and Human Rights (2003) HIV/AIDS and Human Rights International Guidelines (Geneva: Office of the United Nations High Commissioner for Human Rights and the Joint United Nations Programme on HIV/AIDS).

    Google Scholar 

  • UNAIDS/WHO/UNDP (2011) ‘Using TRIPS Flexibilities to Improve Access to HIV Treatment: Policy Brief’, http://asia-pacific.undp.org/practices/hivaids/documents/trips/JC2049_PolicyBrief-TRIPS_eng.pdf/practices/hivaids/documents/trips/JC2049_PolicyBrief-TRIPS_eng.pdf, date accessed 13 July 2012.

  • Velasquez, G. and P. Boulet (1999) Globalization and Access to Drugs: Perspectives on the WTO/TRIPS Agreement, Health Economics and Drugs DAP Series No. 7 (Geneva: WHO).

    Google Scholar 

  • Vivas-Eugui, D. (2003) Regional and Bilateral Agreements and a TRIPS-Plus World: The Free Trade Area of the Americas (FTAA), TRIPS Issues Papers 1 (Geneva: Quaker United Nations Office).

    Google Scholar 

  • Waning, B., M. Kyle, E. Diedrichsen, L. Soucy, J. Hochstadt, T. Barnighausen, and S. Moon (2010) ‘Intervening in Global Markets to Improve Access to HIV/AIDS Treatment: An Analysis of International Policies and the Dynamics of Global Antiretroviral Medicines Markets’, Globalization and Health 6, 9.

    Article  Google Scholar 

  • Watal, J. (2001) Intellectual Property Rights in the WTO and Developing Countries (London: Kluwer Law International).

    Google Scholar 

  • Williams, O. D. (2012) ‘Access to Medicines, Market Failure and Market Intervention: A Tale of Two Regimes’, Global Public Health, Forthcoming.

    Google Scholar 

  • World Health Assembly (2008) Global Strategy and Plan of Action on Public Health, Innovation and Intellectual Property (Vol.WHA61.21), http://apps.who.int/gb/ebwha/pdf_files/A61/A61_R21-en.pdf/gb/ebwha/pdf_files/A61/A61_R21-en.pdf, date accessed 14 August 2012.

  • World Health Organization (1998) Revised Drug Strategy. WHO’s Work in Pharmaceuticals and Essential Drugs (Geneva: World Health Organization).

    Google Scholar 

  • World Trade Organization (1994) ‘Agreement on Trade-Related Aspects of Intellectual Property Rights’, Annex 1C of the Marrakesh Agreement Establishing the

    Google Scholar 

  • World Trade Organization, signed in Marrakesh, Morocco on 15 April. http://www.wto.org/english/tratop_e/trips_e/t_agm0_e.htm, date accessed 10 January 2012.

  • World Trade Organization (2001) Declaration on the TRIPS Agreement and Public Health (WT/MIN(01)/DEC/2 20 November 2001 ed.).

    Google Scholar 

  • Yu, P. K. (2008) ‘Access to Medicines, BRICS Alliances, and Collective Action’, American Journal of Law & Medicine 34, 345–94.

    Google Scholar 

  • Yu, P. K. (2011) ‘TRIPS and Its Achilles’ Heel’, Journal of Intellectual Property Law 18, 479–531.

    Google Scholar 

  • YouTube (2012) ‘Teresa Stanek Rea Tells Congress USPTO Opposes India Compulsory Licence on Patented Cancer Drug’, http://www.youtube.com/watch?v=k9_68z6De9E/watch?v=k9_68z6De9E, date accessed 2 September 2012.

Download references

Authors
  1. Hans Löfgren
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Owain David Williams
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. School of Humanities and Social Sciences, Deakin University, Australia

    Hans Löfgren (Associate Professor) (Associate Professor)

  2. Centre for Health and International Relations, Aberystwyth University, UK

    Owain David Williams (Research Fellow) (Research Fellow)

Copyright information

© 2013 Hans Löfgren and Owain David Williams

About this chapter

Cite this chapter

Löfgren, H., Williams, O.D. (2013). The New Political Economy of Pharmaceuticals: Conformity and Resistance in the Global South. In: Löfgren, H., Williams, O.D. (eds) The New Political Economy of Pharmaceuticals. International Political Economy Series. Palgrave Macmillan, London. https://doi.org/10.1057/9781137315854_1

Download citation

Publish with us

Policies and ethics

Search

Navigation